The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats

Peter Boor, Peter Celec, Ina V. Martin, Luigi Villa, Július Hodosy, Kristína Klenovicsová, Ciro Esposito, Stefan Schäfer, Barbara Albrecht-Küpper, Tammo Ostendorf, August Heidland, Katarína Šebeková

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Recent studies have shown renoprotective effects of the peroxisome proliferator-activated receptor-α (PPAR-α), but its role in kidney fibrosis is unknown. In order to gain insight into this, we examined the effect of a novel PPAR-α agonist, BAY PP1, in two rat models of renal fibrosis: unilateral ureteral obstruction and the 5/6 nephrectomy. In healthy animals, PPAR-α was expressed in tubular but not in interstitial cells. Upon induction of fibrosis, PPAR-α was significantly downregulated, and treatment with BAY PP1 significantly restored its expression. During ureteral obstruction, treatment with BAY PP1 significantly reduced tubulointerstitial fibrosis, proliferation of interstitial fibroblasts, and TGF-Β 1 expression. Treatment with a less potent PPAR-α agonist, fenofibrate, had no effects. Treatment with BAY PP1, initiated in established disease in the 5/6 nephrectomy, halted the decline of renal function and significantly ameliorated renal fibrosis. In vitro, BAY PP1 had no direct effect on renal fibroblasts but reduced collagen, fibronectin, and TGF-Β 1 expression in tubular cells. Conditioned media of BAY PP1-treated tubular cells reduced fibroblast proliferation. Thus, renal fibrosis is characterized by a reduction of PPAR-α expression, and treatment with BAY PP1 restores PPAR-α expression and ameliorates renal fibrosis by modulating the cross-talk between tubular cells and fibroblasts. Hence, potent PPAR-α agonists might be useful in the treatment of renal fibrosis.

Original languageEnglish
Pages (from-to)1182-1197
Number of pages16
JournalKidney International
Volume80
Issue number11
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Peroxisome Proliferator-Activated Receptors
Fibrosis
Kidney
Fibroblasts
Ureteral Obstruction
Nephrectomy
Fenofibrate
2-((4-(((2-methoxyethyl)(6-(3-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)methyl)phenyl)sulfanyl)-2-methylpropanoic acid
Conditioned Culture Medium
Fibronectins
Collagen
Down-Regulation

ASJC Scopus subject areas

  • Nephrology

Cite this

Boor, P., Celec, P., Martin, I. V., Villa, L., Hodosy, J., Klenovicsová, K., ... Šebeková, K. (2011). The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney International, 80(11), 1182-1197. https://doi.org/10.1038/ki.2011.254

The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats. / Boor, Peter; Celec, Peter; Martin, Ina V.; Villa, Luigi; Hodosy, Július; Klenovicsová, Kristína; Esposito, Ciro; Schäfer, Stefan; Albrecht-Küpper, Barbara; Ostendorf, Tammo; Heidland, August; Šebeková, Katarína.

In: Kidney International, Vol. 80, No. 11, 12.2011, p. 1182-1197.

Research output: Contribution to journalArticle

Boor, P, Celec, P, Martin, IV, Villa, L, Hodosy, J, Klenovicsová, K, Esposito, C, Schäfer, S, Albrecht-Küpper, B, Ostendorf, T, Heidland, A & Šebeková, K 2011, 'The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats', Kidney International, vol. 80, no. 11, pp. 1182-1197. https://doi.org/10.1038/ki.2011.254
Boor, Peter ; Celec, Peter ; Martin, Ina V. ; Villa, Luigi ; Hodosy, Július ; Klenovicsová, Kristína ; Esposito, Ciro ; Schäfer, Stefan ; Albrecht-Küpper, Barbara ; Ostendorf, Tammo ; Heidland, August ; Šebeková, Katarína. / The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats. In: Kidney International. 2011 ; Vol. 80, No. 11. pp. 1182-1197.
@article{97281ac197a840b99c18ef30df6669fa,
title = "The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats",
abstract = "Recent studies have shown renoprotective effects of the peroxisome proliferator-activated receptor-α (PPAR-α), but its role in kidney fibrosis is unknown. In order to gain insight into this, we examined the effect of a novel PPAR-α agonist, BAY PP1, in two rat models of renal fibrosis: unilateral ureteral obstruction and the 5/6 nephrectomy. In healthy animals, PPAR-α was expressed in tubular but not in interstitial cells. Upon induction of fibrosis, PPAR-α was significantly downregulated, and treatment with BAY PP1 significantly restored its expression. During ureteral obstruction, treatment with BAY PP1 significantly reduced tubulointerstitial fibrosis, proliferation of interstitial fibroblasts, and TGF-Β 1 expression. Treatment with a less potent PPAR-α agonist, fenofibrate, had no effects. Treatment with BAY PP1, initiated in established disease in the 5/6 nephrectomy, halted the decline of renal function and significantly ameliorated renal fibrosis. In vitro, BAY PP1 had no direct effect on renal fibroblasts but reduced collagen, fibronectin, and TGF-Β 1 expression in tubular cells. Conditioned media of BAY PP1-treated tubular cells reduced fibroblast proliferation. Thus, renal fibrosis is characterized by a reduction of PPAR-α expression, and treatment with BAY PP1 restores PPAR-α expression and ameliorates renal fibrosis by modulating the cross-talk between tubular cells and fibroblasts. Hence, potent PPAR-α agonists might be useful in the treatment of renal fibrosis.",
author = "Peter Boor and Peter Celec and Martin, {Ina V.} and Luigi Villa and J{\'u}lius Hodosy and Krist{\'i}na Klenovicsov{\'a} and Ciro Esposito and Stefan Sch{\"a}fer and Barbara Albrecht-K{\"u}pper and Tammo Ostendorf and August Heidland and Katar{\'i}na Šebekov{\'a}",
year = "2011",
month = "12",
doi = "10.1038/ki.2011.254",
language = "English",
volume = "80",
pages = "1182--1197",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats

AU - Boor, Peter

AU - Celec, Peter

AU - Martin, Ina V.

AU - Villa, Luigi

AU - Hodosy, Július

AU - Klenovicsová, Kristína

AU - Esposito, Ciro

AU - Schäfer, Stefan

AU - Albrecht-Küpper, Barbara

AU - Ostendorf, Tammo

AU - Heidland, August

AU - Šebeková, Katarína

PY - 2011/12

Y1 - 2011/12

N2 - Recent studies have shown renoprotective effects of the peroxisome proliferator-activated receptor-α (PPAR-α), but its role in kidney fibrosis is unknown. In order to gain insight into this, we examined the effect of a novel PPAR-α agonist, BAY PP1, in two rat models of renal fibrosis: unilateral ureteral obstruction and the 5/6 nephrectomy. In healthy animals, PPAR-α was expressed in tubular but not in interstitial cells. Upon induction of fibrosis, PPAR-α was significantly downregulated, and treatment with BAY PP1 significantly restored its expression. During ureteral obstruction, treatment with BAY PP1 significantly reduced tubulointerstitial fibrosis, proliferation of interstitial fibroblasts, and TGF-Β 1 expression. Treatment with a less potent PPAR-α agonist, fenofibrate, had no effects. Treatment with BAY PP1, initiated in established disease in the 5/6 nephrectomy, halted the decline of renal function and significantly ameliorated renal fibrosis. In vitro, BAY PP1 had no direct effect on renal fibroblasts but reduced collagen, fibronectin, and TGF-Β 1 expression in tubular cells. Conditioned media of BAY PP1-treated tubular cells reduced fibroblast proliferation. Thus, renal fibrosis is characterized by a reduction of PPAR-α expression, and treatment with BAY PP1 restores PPAR-α expression and ameliorates renal fibrosis by modulating the cross-talk between tubular cells and fibroblasts. Hence, potent PPAR-α agonists might be useful in the treatment of renal fibrosis.

AB - Recent studies have shown renoprotective effects of the peroxisome proliferator-activated receptor-α (PPAR-α), but its role in kidney fibrosis is unknown. In order to gain insight into this, we examined the effect of a novel PPAR-α agonist, BAY PP1, in two rat models of renal fibrosis: unilateral ureteral obstruction and the 5/6 nephrectomy. In healthy animals, PPAR-α was expressed in tubular but not in interstitial cells. Upon induction of fibrosis, PPAR-α was significantly downregulated, and treatment with BAY PP1 significantly restored its expression. During ureteral obstruction, treatment with BAY PP1 significantly reduced tubulointerstitial fibrosis, proliferation of interstitial fibroblasts, and TGF-Β 1 expression. Treatment with a less potent PPAR-α agonist, fenofibrate, had no effects. Treatment with BAY PP1, initiated in established disease in the 5/6 nephrectomy, halted the decline of renal function and significantly ameliorated renal fibrosis. In vitro, BAY PP1 had no direct effect on renal fibroblasts but reduced collagen, fibronectin, and TGF-Β 1 expression in tubular cells. Conditioned media of BAY PP1-treated tubular cells reduced fibroblast proliferation. Thus, renal fibrosis is characterized by a reduction of PPAR-α expression, and treatment with BAY PP1 restores PPAR-α expression and ameliorates renal fibrosis by modulating the cross-talk between tubular cells and fibroblasts. Hence, potent PPAR-α agonists might be useful in the treatment of renal fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=81155131056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155131056&partnerID=8YFLogxK

U2 - 10.1038/ki.2011.254

DO - 10.1038/ki.2011.254

M3 - Article

VL - 80

SP - 1182

EP - 1197

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 11

ER -